KIM-1 as a Prognostic Marker in Renal Cell Carcinoma.

IF 5.6 2区医学 Q1 UROLOGY & NEPHROLOGY

European urology focus Pub Date : 2025-07-05 DOI:10.1016/j.euf.2025.06.012

Clara Steiner, Marc Machaalani, Joseph V Bonventre, David F McDermott, Toni K Choueiri, Wenxin Xu

引用次数: 0

Abstract

There is an unmet need for a noninvasive biomarker in renal cell carcinoma. KIM-1 has emerged as a compelling candidate according to retrospective evidence and post hoc analyses of prospective trials. Prospective studies are needed for validation and clinical implementation.

查看原文本刊更多论文

KIM-1作为肾细胞癌的预后标志物。

目前对肾细胞癌的非侵入性生物标志物的需求尚未得到满足。根据回顾性证据和前瞻性试验的事后分析，KIM-1已成为令人信服的候选药物。需要前瞻性研究来验证和临床实施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.